SHANGHAI, May 1, 2012 /PRNewswire-Asia-FirstCall/ -- ShangPharma Corporation (NYSE: SHP) ("ShangPharma" or the "Company"), a leading China-based pharmaceutical and biotechnology research and development outsourcing company, today announced that it has filed its annual report on Form 20-F for the year ended December 31, 2011 with the United States Securities and Exchange Commission (the "SEC"). The annual report can be accessed on ShangPharma's website at http://ir.shangpharma.com under the Investor Relations section. ShangPharma will provide a hard copy of its annual report on Form 20-F containing complete audited financial statements free of charge to its shareholders and ADS holders upon request. Requests should be directed to Ms. Lan Xie, VP of Finance and Investor Relations, by email at email@example.com.
ABOUT SHANGPHARMA CORPORATION
ShangPharma Corporation (NYSE: SHP) is a leading China-based contract research organization providing high-quality and cost-effective services for the pharmaceutical and biotechnology industry. It offers a broad range of high-quality, integrated services across the drug discovery and development process to help international and Chinese pharmaceutical and biotechnology companies discover and develop novel drug candidates efficiently. ShangPharma's services consist of discovery chemistry, discovery biology and preclinical development, pharmaceutical development and biologics services. For more information, please visit www.shangpharma.com.
For further information, please contact:
Ms. Lan Xie
VP of Finance and Investor Relations
Mr. Josh Gartner
|SOURCE ShangPharma Corporation|
Copyright©2010 PR Newswire.
All rights reserved